Secukinumab
Indication
Moderate to Severe Plaque Psoriasis (NICE TA350)
NICE TA 350 - Secukinumab for treating moderate to severe plaque psoriasis
Red
Brand:
Cosentyx ®
Nice TA:
350
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Skin
Background
Secukinumab is recommended, as an option for treating adults with plaque psoriasis as per NICE TA 350
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine
Supporting documents: